Senses Disorder TRIZ Cases

Micellar aqueous retinol keeps parenteral vitamin A clear, filter-sterilizable, and free of excipients linked to allergic reactions.

A chimeric opsin with mGluR4 domains enables retinal ganglion cells to detect light through endogenous signaling and restore partial vision.

A wearable annular eye reservoir uses a diaphragm and one-way valves to improve ocular drug absorption and dosing consistency without surgery.

By delivering atropine, herbal extracts, and vitamins through the eyelid, this case relieves eye fatigue while avoiding drop-induced irritation and infection.

Clinical-grade corneal endothelial cells are generated from iPSCs and cryopreserved to ease donor shortages and reduce graft rejection.

A biodegradable coating on high-payload supraparticles suppresses burst release and enables sustained drug delivery with lower dosing frequency.

A histidine-buffered liquid VEGF antagonist uses salt, carbohydrate, and polysorbate to limit particles and protein degradation during storage.

Indole-3-carbinol reduces ocular inflammation and boosts tear production to address dry eye with longer-lasting relief and fewer side effects.

Reduced hyaluronic acid and retained HC-HA/PTX3 help amniotic membrane tissue adhere to the eye while preserving lubrication and shelf-stability.

A preservative-free blend of povidone and hydrolyzed polyvinyl alcohol lubricates dry eyes while maintaining pH, osmolarity, and low irritation.

Capsid mutations and peptide insertions improve intravitreal AAV delivery to photoreceptor and RPE cells across full retinal layers.

Novel heterocyclic compounds inhibit PI3K delta and mTOR to improve immune response control and treatment of cancer-related disease.

AAV delivery of TAFA-encoding sequences enables sustained retinal repair, addressing limited treatment options for retinal and macular disease.

An oral bio-gold and bio-zinc composition addresses vascular complications while avoiding invasive eye treatments and reducing side effects.

Modified Fc mutations let a hybrid nuclease clear extracellular RNA and DNA while limiting Fcγ receptor binding, cytotoxicity, and lupus immune activation.

Sesamin is combined with topical NGF to reduce eye pain and irritation, improving tolerability for ophthalmic disorder treatment.

Solid nicotine salts and co-crystals replace hard-to-handle nicotine oil with stable, purer, more soluble forms for easier product incorporation.

Targeted amino acid substitutions in Cas variants improve DNA binding and cleavage activity, helping expand gene editing use cases.

Finely divided silicon dioxide adsorbs serine proteases and zymogens from plasma-derived proteins, lowering thromboembolic risk.

Blocking PTGDS with AT-56 lowers PGD2, ROS, and apoptosis in lens epithelial cells to slow age-related cataract progression.

An amphiphilic linker lets poorly water-soluble nucleic acid drugs bind within a hydrogel while preserving transparency for contact lens delivery.

Multi-stage stimulation and resting cultures raise stable FoxP3 and suppressive marker expression for stronger human T cell immunosuppression.

Topical or implant nintedanib suppresses fibrotic wound healing after glaucoma filtration surgery to preserve drainage and prolong pressure reduction.

Truncated CR1-derived polypeptides bind C3b and cross Bruch's membrane to regulate local complement activation in AMD.

Multi-step alcohol fractionation with ion exchange chromatography cuts IgG loss during purification and raises IVIG yield and purity.

Gut-derived urolithins and ellagic acid precursors raise autophagy and support longevity with less regimen complexity and toxicity risk.

Controlled copper eye drops raise corneal lysyl oxidase activity to strengthen cross-linking and slow myopic progression while limiting over-flattening.

Cell-specific cochlear promoters enable targeted transgene expression in inner hair cells to improve function, survival, and hearing loss treatment.

A three-part oral composition uses lutein ester with Plukenetia and citrus peel oils to relieve asthenopia, improve eyesight, and reduce greasy taste.

Cell culture parameter changes keep aflibercept truncation variants at or below 20%, preserving activity without extra purification steps.

Sized nanostructure conjugates block extrasynaptic NMDA receptors while preserving synaptic signaling, reducing side effects in neuroprotection.

Blocking Neuropilin-1A redirects angiogenesis to ischemic retina while reducing vascular leakage and pathological neovascularization.

A multi-component eye care composition combines L-ergothioneine, taurine, and sodium hyaluronate to relieve dryness, fatigue, itchiness, and inflammation.

An irradiated mouse model links microglial activation to retinal degeneration, helping identify genetic drivers and therapeutic targets.

Ion-exchange steps tuned by pH and salt gradients narrow aflibercept pI distribution, improving purity and yield for ophthalmic use.

Novel 1,4-substituted piperidines balance strong P2X7 antagonism, cross-species activity, and brain delivery for inflammatory and neurological disease treatment.

Miro1 reduction paired with companion biomarker assays helps monitor Parkinson's treatment response and restore mitophagy in damaged mitochondria.

CRISPR/Cas9 delivery by AAV vectors edits CEP290 in retinal cells to restore functional protein expression without uncontrolled gene augmentation.

Engineered IGF-1 variants reduce IGFBP binding to improve local action in meibomian glands, supporting lipid production and corneal healing.

A viscoelastic, thermogelling AAV formulation extends suprachoroidal residence while limiting spread and avoiding risks of intravitreal or subretinal delivery.

A cellulosic stabilizer keeps 25-hydroxyvitamin D release profiles consistent during storage, improving sustained delivery and serum control.

A biodegradable PLGA-PLA polymer matrix enables near-linear ocular drug release for up to six months while reducing repeat injections and adverse effects.

Nucleoside compounds inhibit LINE-1 retrotransposition to enable treatment and prevention of neurodegenerative, autoimmune, and age-associated diseases.

Two AAV vectors split and recombine the oversized OTOF gene to restore functional otoferlin expression in cochlear cells for sensorineural hearing loss.

Cell-specific SLC26A4 enhancers and promoters drive therapeutic gene expression in inner ear cells while limiting off-target effects.

rAAV delivery turns ocular tissue into a local antibody depot, sustaining anti-C3 or anti-C5 levels for AMD with fewer injections.

An Fc-linked hybrid nuclease extends serum half-life while degrading nucleoprotein antigens to lower anti-RNA antibodies and immune activation.

IGF-IR inhibitory antibodies address relapsed or nonresponsive thyroid eye disease by reducing proptosis, CAS, and diplopia after prior treatment.

Targeting CXCR1/CXCR2 with CXCL8 inhibitors lowers NET-related inflammation and VEGF to treat diabetic retinopathy and neuropathy.

A CFTR-activating compound boosts chloride and fluid secretion to improve constipation treatment and increase lacrimation in dry eye.